Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated platform designed to accelerate enzyme catalyst development for biomanufacturing. The platform merges computational enzyme engineering with practical process development, aiming to deliver solutions that are both predictable in silico and stable at industrial scale.
Traditional enzyme development approaches struggle to meet the speed requirements of iterative product development. AI brings value by predicting enzyme candidates for given reactions, designing enzymes constrained by process parameters, and leveraging molecular features to anticipate performance. This reduces the need for extensive experimental testing, saving R&D costs and lowering the risk of process failure by identifying suitable biocatalysts earlier.
The platform offers three specialized service modules: AI-Driven Biocatalysis Solutions for end-to-end discovery and engineering; AI-Driven Industrial Biocatalysis for scale-up and commercialization; and AI-Driven Green Biocatalysis for sustainability-focused processes. The workflow includes computational screening, process optimization, and scale-up evaluation, reducing the design-build-test-learn cycle from 12–24 months to 8–12 months for moderately complex targets.
In a recent case study, researchers used the platform for transaminase engineering to produce sitagliptin, a diabetes drug. AI selected five variants with nine mutations each, achieving high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes delivered enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up.
The platform addresses key challenges in pharmaceuticals, agrochemicals, food, fine chemicals, and personal care. In pharma, it enables asymmetric synthesis of chiral intermediates and replacement of hazardous reagents. Agrochemicals benefit from refined toxicology profiles, while the food industry achieves cleaner labels through enzymatic modification. Fine chemicals and personal care sectors explore high-value conversions with milder, sustainable processes.
For more details on the platform's capabilities, visit Creative Enzymes' AI-Driven Biocatalysis Solutions page. The platform's structured approach ensures development decisions are driven by empirical evidence, bridging the gap between lab-scale performance and commercial production.
